Target intelligence / Profile preview

High-mannose N-glycan (HMG) (HMG)

Target
HMG
Molecular classification
Glycan, Carbohydrate, Post-translational modification
01

Overview

High-mannose N-glycans (HMGs) are a class of oligosaccharides characterized by a core of two N-acetylglucosamine residues and five to nine mannose residues (Man5-Man9GlcNAc2). While typically processed into complex glycans in healthy human cells, they are often retained in high density on the surface glycoproteins of enveloped viruses, such as HIV-1 gp120 and the SARS-CoV-2 Spike protein, due to steric hindrance or altered biosynthetic pathways [2.1.1, 2.4.5]. These mannose-rich motifs serve as a "glycan shield" to evade the host immune system but also act as specific attachment factors for host receptors like DC-SIGN [2.1.3, 2.4.5]. Furthermore, aberrant high-mannose glycosylation is a hallmark of certain cancers and is prominently displayed on tumor-derived extracellular vesicles (EVs), making them valuable biomarkers for liquid biopsies [3.2.1, 3.2.3]. Consequently, HMGs have emerged as attractive therapeutic targets for broad-spectrum antivirals and cancer diagnostics [2.4.2, 3.2.2]. Therapeutic agents targeting these motifs include natural lectins like Griffithsin and broadly neutralizing antibodies like 2G12, which bind and neutralize pathogens by blocking entry or inducing aggregation [2.3.1, 2.4.1]. Despite their potential, challenges include the risk of off-target binding to host glycoproteins and the immunogenicity of non-human lectins [2.4.3, 3.3.2].

Other names
Oligomannose-type glycanMannose-rich N-glycan motifMan5-Man9GlcNAc2Trimer-associated mannose-patchTAMPHigh-mannose cluster
02

Mechanism of action

Binding to high-mannose glycans blocks viral entry and fusion, prevents attachment to host receptors (e.g., DC-SIGN), and can induce aggregation of viral particles or extracellular vesicles.

03

Biological functions

Protein foldingImmune evasionViral entryCell-cell communicationProtein stabilityHost receptor attachment
04

Disease associations

InfectionCancerInflammation
05

Safety considerations

Off-target binding to host glycoproteinsImmunogenicity of non-human lectinsViral resistance through loss of glycosylation sitesPotential for mitogenic activity in certain lectins
06

Interacting drugs

Griffithsin

7 more in the full profile.

07

Biomarkers

High-mannose glycan levels on extracellular vesicles2G12-binding motifsOAA-binding glycan signatures

Beyond the preview

Go deeper on High-mannose N-glycan (HMG) (HMG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on High-mannose N-glycan (HMG) (HMG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call